2903 T3D2861 Daunorubicin Daunorubicin is only found in individuals that have used or taken this drug. It is a very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem]Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. 20830-81-3 30323 C27H29NO10 527.179150 White powder. 208-209°C 39.2 mg/L Intravenous Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Hepatic Route of Elimination: Twenty-five percent of an administered dose of daunorubicin hydrochloride is eliminated in an active form by urinary excretion and an estimated 40% by biliary excretion. Half Life: 18.5 hours LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV) 2B, possibly carcinogenic to humans. (L135) For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. Antibiotic resistance. Toxic manifestations of Daunorubicin include bone marrow depression, stomatitis, alopecia, gastrointestinal disturbances, and dermatological manifestations. Cardiac toxicity is a pecular effect. (A723) symptoms include gastrointestinal disturbances. (A723) Infuse 10 to 20 mL/kg isotonic fluid. If hypotension persists, administer dopamine. (A704) 2009-07-21T20:27:25Z 2026-05-14T16:46:17Z Daunorubicin C01907 4330 Daunorubicin DB00694 DM1 true COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O C27H29NO10 InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1 STQGQHZAVUOBTE-VGBVRHCVSA-N 527.5199 527.179146153 Exogenous Solid 1.83 HMDB14832 CHEMBL178 28163 <p>Sylvie Pinnert, Leon Ninet, Jean Preud&#8217;Homme, &#8220;Antibiotic daunorubicin and its preparation.&#8221; U.S. Patent US3989598, issued March, 1965.</p> CHEM002249 DTXSID7022883 NS00003308 (8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione 185.84 132.89149999999998 52.94465268518259 4 11 5 9.530939095303156 8.935714482162204 1 5 1.68 -2.93 6.27e-01 g/l